NO330508B1 - Blanding bestaende av syntetisk fosfodiester-nukleotidsekvens og anvendelse derav. - Google Patents
Blanding bestaende av syntetisk fosfodiester-nukleotidsekvens og anvendelse derav. Download PDFInfo
- Publication number
- NO330508B1 NO330508B1 NO20022820A NO20022820A NO330508B1 NO 330508 B1 NO330508 B1 NO 330508B1 NO 20022820 A NO20022820 A NO 20022820A NO 20022820 A NO20022820 A NO 20022820A NO 330508 B1 NO330508 B1 NO 330508B1
- Authority
- NO
- Norway
- Prior art keywords
- cells
- base
- seq
- sequences
- cancer
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 239000002773 nucleotide Substances 0.000 title claims abstract description 6
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 74
- 201000011510 cancer Diseases 0.000 claims abstract description 46
- 102000011727 Caspases Human genes 0.000 claims abstract description 30
- 108010076667 Caspases Proteins 0.000 claims abstract description 30
- 230000004913 activation Effects 0.000 claims abstract description 30
- 230000035755 proliferation Effects 0.000 claims abstract description 26
- 230000005764 inhibitory process Effects 0.000 claims abstract description 25
- 238000004519 manufacturing process Methods 0.000 claims abstract description 22
- 230000025084 cell cycle arrest Effects 0.000 claims abstract description 16
- 102000004127 Cytokines Human genes 0.000 claims abstract description 15
- 108090000695 Cytokines Proteins 0.000 claims abstract description 15
- 230000006698 induction Effects 0.000 claims abstract description 13
- 230000006882 induction of apoptosis Effects 0.000 claims abstract description 9
- 239000003937 drug carrier Substances 0.000 claims abstract description 8
- 210000000987 immune system Anatomy 0.000 claims abstract description 8
- 230000004044 response Effects 0.000 claims abstract description 5
- 102000013462 Interleukin-12 Human genes 0.000 claims description 23
- 108010065805 Interleukin-12 Proteins 0.000 claims description 23
- 208000032839 leukemia Diseases 0.000 claims description 23
- 102000004889 Interleukin-6 Human genes 0.000 claims description 15
- 108090001005 Interleukin-6 Proteins 0.000 claims description 15
- 239000002246 antineoplastic agent Substances 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 208000026310 Breast neoplasm Diseases 0.000 claims description 12
- 206010006187 Breast cancer Diseases 0.000 claims description 11
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 11
- 229940127089 cytotoxic agent Drugs 0.000 claims description 11
- 102000003814 Interleukin-10 Human genes 0.000 claims description 10
- 108090000174 Interleukin-10 Proteins 0.000 claims description 10
- 206010060862 Prostate cancer Diseases 0.000 claims description 9
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 206010033128 Ovarian cancer Diseases 0.000 claims description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 7
- 102000003777 Interleukin-1 beta Human genes 0.000 claims description 6
- 108090000193 Interleukin-1 beta Proteins 0.000 claims description 6
- 206010025323 Lymphomas Diseases 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
- 206010039491 Sarcoma Diseases 0.000 claims description 5
- 206010027476 Metastases Diseases 0.000 claims description 4
- 230000000340 anti-metabolite Effects 0.000 claims description 4
- 229940100197 antimetabolite Drugs 0.000 claims description 4
- 239000002256 antimetabolite Substances 0.000 claims description 4
- 229940100198 alkylating agent Drugs 0.000 claims description 3
- 239000002168 alkylating agent Substances 0.000 claims description 3
- 210000000481 breast Anatomy 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 208000011646 secondary carcinoma Diseases 0.000 claims description 3
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 239000003667 hormone antagonist Substances 0.000 claims description 2
- 230000002611 ovarian Effects 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 145
- 241000699670 Mus sp. Species 0.000 description 44
- 210000001744 T-lymphocyte Anatomy 0.000 description 34
- 230000006907 apoptotic process Effects 0.000 description 26
- 108090000397 Caspase 3 Proteins 0.000 description 25
- 102100029855 Caspase-3 Human genes 0.000 description 22
- 230000000694 effects Effects 0.000 description 18
- 230000004663 cell proliferation Effects 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 15
- 150000004713 phosphodiesters Chemical class 0.000 description 15
- 108090000567 Caspase 7 Proteins 0.000 description 14
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 14
- 102100038902 Caspase-7 Human genes 0.000 description 13
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 13
- 241001529936 Murinae Species 0.000 description 12
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 12
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 12
- 230000022131 cell cycle Effects 0.000 description 11
- 102000008297 Nuclear Matrix-Associated Proteins Human genes 0.000 description 10
- 108010035916 Nuclear Matrix-Associated Proteins Proteins 0.000 description 10
- 230000006052 T cell proliferation Effects 0.000 description 10
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 230000009702 cancer cell proliferation Effects 0.000 description 9
- 229960002949 fluorouracil Drugs 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 7
- 241000282465 Canis Species 0.000 description 7
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- 239000011575 calcium Substances 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- 229960001603 tamoxifen Drugs 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 230000000118 anti-neoplastic effect Effects 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 208000000389 T-cell leukemia Diseases 0.000 description 5
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 5
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000016396 cytokine production Effects 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000035800 maturation Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- OZLGRUXZXMRXGP-UHFFFAOYSA-N Fluo-3 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(Cl)C(=O)C=C3OC3=CC(O)=C(Cl)C=C32)N(CC(O)=O)CC(O)=O)=C1 OZLGRUXZXMRXGP-UHFFFAOYSA-N 0.000 description 4
- 230000018199 S phase Effects 0.000 description 4
- 239000006180 TBST buffer Substances 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 239000008365 aqueous carrier Substances 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
- 229960004316 cisplatin Drugs 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- -1 growth-inhibiting Proteins 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 125000004430 oxygen atom Chemical group O* 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- SUEGWIXYCHISPX-UHFFFAOYSA-N sulfane trihydroxy(sulfanylidene)-lambda5-phosphane Chemical compound OP(O)(O)=S.S SUEGWIXYCHISPX-UHFFFAOYSA-N 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 125000004434 sulfur atom Chemical group 0.000 description 4
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 3
- 102000004121 Annexin A5 Human genes 0.000 description 3
- 102000003952 Caspase 3 Human genes 0.000 description 3
- 230000006820 DNA synthesis Effects 0.000 description 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 3
- 241000282560 Macaca mulatta Species 0.000 description 3
- 241000282577 Pan troglodytes Species 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 230000010437 erythropoiesis Effects 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 3
- 102000003390 tumor necrosis factor Human genes 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000187481 Mycobacterium phlei Species 0.000 description 2
- 108091093105 Nuclear DNA Proteins 0.000 description 2
- 102000007999 Nuclear Proteins Human genes 0.000 description 2
- 108010089610 Nuclear Proteins Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108010017842 Telomerase Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 230000010094 cellular senescence Effects 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000013861 fat-free Nutrition 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000019734 interleukin-12 production Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229940055036 mycobacterium phlei Drugs 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 108091035539 telomere Proteins 0.000 description 2
- 102000055501 telomere Human genes 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- AOUOVFRSCMDPFA-QSDJMHMYSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-methylbutanoyl]amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(O)=O AOUOVFRSCMDPFA-QSDJMHMYSA-N 0.000 description 1
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- YYYARFHFWYKNLF-UHFFFAOYSA-N 4-[(2,4-dimethylphenyl)diazenyl]-3-hydroxynaphthalene-2,7-disulfonic acid Chemical compound CC1=CC(C)=CC=C1N=NC1=C(O)C(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=C12 YYYARFHFWYKNLF-UHFFFAOYSA-N 0.000 description 1
- 102000015693 Actin Depolymerizing Factors Human genes 0.000 description 1
- 108010038798 Actin Depolymerizing Factors Proteins 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 102000004580 Aspartic Acid Proteases Human genes 0.000 description 1
- 108010017640 Aspartic Acid Proteases Proteins 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- WTYQNWDZSGLSLW-UHFFFAOYSA-O CC1=CSC(C)=N1.C1=CC=CC=C1[NH+]1C(C=2C=CC=CC=2)=NN=N1 Chemical compound CC1=CSC(C)=N1.C1=CC=CC=C1[NH+]1C(C=2C=CC=CC=2)=NN=N1 WTYQNWDZSGLSLW-UHFFFAOYSA-O 0.000 description 1
- 101100005766 Caenorhabditis elegans cdf-1 gene Proteins 0.000 description 1
- 102000004041 Caspase 7 Human genes 0.000 description 1
- 102100035904 Caspase-1 Human genes 0.000 description 1
- 108090000426 Caspase-1 Proteins 0.000 description 1
- 102000004068 Caspase-10 Human genes 0.000 description 1
- 108090000572 Caspase-10 Proteins 0.000 description 1
- 102100032616 Caspase-2 Human genes 0.000 description 1
- 108090000552 Caspase-2 Proteins 0.000 description 1
- 102100025597 Caspase-4 Human genes 0.000 description 1
- 101710090338 Caspase-4 Proteins 0.000 description 1
- 102100038916 Caspase-5 Human genes 0.000 description 1
- 101710090333 Caspase-5 Proteins 0.000 description 1
- 102100026548 Caspase-8 Human genes 0.000 description 1
- 108090000538 Caspase-8 Proteins 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000012746 DNA damage checkpoint Effects 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 102100031690 Erythroid transcription factor Human genes 0.000 description 1
- 101710100588 Erythroid transcription factor Proteins 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 230000004668 G2/M phase Effects 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000573199 Homo sapiens Protein PML Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000049772 Interleukin-16 Human genes 0.000 description 1
- 101800003050 Interleukin-16 Proteins 0.000 description 1
- 102000006835 Lamins Human genes 0.000 description 1
- 108010047294 Lamins Proteins 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 102100021010 Nucleolin Human genes 0.000 description 1
- XVZUMQAMCYSUMS-SIUGBPQLSA-N OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 XVZUMQAMCYSUMS-SIUGBPQLSA-N 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101000708422 Podarcis siculus Tissue- and phase-specific nuclear protein Proteins 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 101000933603 Rattus norvegicus Protein BTG1 Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000018486 cell cycle phase Effects 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000002435 cytoreductive effect Effects 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 230000000547 effect on apoptosis Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 102000054896 human PML Human genes 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000019189 interleukin-1 beta production Effects 0.000 description 1
- 230000031261 interleukin-10 production Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229920000831 ionic polymer Polymers 0.000 description 1
- 210000005053 lamin Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 101150025333 murA gene Proteins 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108010044762 nucleolin Proteins 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003651 pro-proliferative effect Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000003277 telomerase inhibitor Substances 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17032599P | 1999-12-13 | 1999-12-13 | |
| US22892500P | 2000-08-29 | 2000-08-29 | |
| PCT/CA2000/001467 WO2001044465A2 (fr) | 1999-12-13 | 2000-12-12 | Oligonucleotides synthetiques utiles du point de vue therapeutique |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20022820D0 NO20022820D0 (no) | 2002-06-13 |
| NO20022820L NO20022820L (no) | 2002-08-08 |
| NO330508B1 true NO330508B1 (no) | 2011-05-09 |
Family
ID=26865979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20022820A NO330508B1 (no) | 1999-12-13 | 2002-06-13 | Blanding bestaende av syntetisk fosfodiester-nukleotidsekvens og anvendelse derav. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7157436B2 (fr) |
| EP (2) | EP1867718B1 (fr) |
| JP (1) | JP4772245B2 (fr) |
| KR (1) | KR100829646B1 (fr) |
| CN (2) | CN101491536B (fr) |
| AT (2) | ATE370231T1 (fr) |
| AU (1) | AU785212B2 (fr) |
| CA (1) | CA2393808A1 (fr) |
| CZ (1) | CZ20022372A3 (fr) |
| DE (2) | DE60036019T2 (fr) |
| DK (2) | DK1238070T3 (fr) |
| ES (2) | ES2288883T3 (fr) |
| HU (1) | HUP0300627A3 (fr) |
| IL (2) | IL150196A0 (fr) |
| MX (1) | MXPA02005842A (fr) |
| NO (1) | NO330508B1 (fr) |
| PT (1) | PT1238070E (fr) |
| WO (1) | WO2001044465A2 (fr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030032610A1 (en) | 1996-06-03 | 2003-02-13 | Gilchrest Barbara A. | Method to inhibit cell growth using oligonucleotides |
| US7960540B2 (en) | 1999-04-08 | 2011-06-14 | Advanced Cancer Therapeutics, Llc | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
| US8114850B2 (en) | 1999-04-08 | 2012-02-14 | Advanced Cancer Therapeutics, Llc | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
| ES2296615T3 (es) | 1999-04-08 | 2008-05-01 | Antisoma Research Limited | Actividad antiproliferativa de oligonucleotidos ricos en g y procedimiento de uso de los mismos para su union a la nucleolina. |
| US6949520B1 (en) * | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
| DK1238070T3 (da) * | 1999-12-13 | 2007-12-03 | Bioniche Life Sciences Inc | Terapeutisk anvendelige syntetiske oligonucleotider |
| JP2004507469A (ja) | 2000-08-29 | 2004-03-11 | バイオニケ ライフ サイエンシーズ インコーポレイテッド | Ｆａｓおよびｆａｓｌ発現の調整 |
| ES2307568T3 (es) * | 2000-12-08 | 2008-12-01 | Coley Pharmaceutical Gmbh | Acidos nucleicos de tipo cpg y metodos de uso de los mismos. |
| US7087586B2 (en) * | 2001-04-24 | 2006-08-08 | Bioniche Life Sciences, Inc. | Oligonucleotide compositions and their use to induce differentiation of cells |
| KR100943567B1 (ko) * | 2001-08-17 | 2010-02-22 | 바이오니취 라이프 사이언시즈 인코포레이티드 | 세포사멸-유도성 포스포디에스테르올리고뉴클레오타이드의 입체구조-활성 관계성 |
| MXPA04002530A (es) * | 2001-10-03 | 2004-05-31 | Bioniche Life Sciences Inc | Oligonucleotidos de treitilenglicol colesteril terapeuticamente utiles. |
| EP1497424A1 (fr) * | 2002-04-22 | 2005-01-19 | Bioniche Life Sciences Inc. | Compositions d'oligonucleotides et leur utilisation pour la modulation de reponses immunitaires |
| CA2521050A1 (fr) * | 2003-04-02 | 2004-10-14 | Coley Pharmaceutical Group, Ltd. | Formulations de type huile-dans-l'eau a base d'acides nucleiques immunostimulateurs, et procedes d'utilisation associes |
| JP2006528697A (ja) * | 2003-05-16 | 2006-12-21 | イデラ ファーマシューティカルズ インコーポレイテッド | イムノマーを化学療法剤と組み合わせて用いる、癌の相乗的処置 |
| US20080009455A9 (en) * | 2005-02-24 | 2008-01-10 | Coley Pharmaceutical Group, Inc. | Immunostimulatory oligonucleotides |
| CA2600440A1 (fr) * | 2005-03-09 | 2006-09-21 | Baylor College Of Medicine | Inversion directe de la fonction inhibitrice des lymphocytes t regulateurs de cd4+ via la signalisation du recepteur 8 de type toll |
| EP1924279A2 (fr) * | 2005-09-07 | 2008-05-28 | The Secretary of State for Defence | Vaccin contenant un adjuvant |
| ES2658626T3 (es) * | 2009-02-12 | 2018-03-12 | Curna, Inc. | Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de células gliales (GDNF) por inhibición de transcrito antisentido natural a GDNF |
| GB0906234D0 (en) | 2009-04-14 | 2009-05-20 | Secr Defence | Vaccine |
| KR100998365B1 (ko) | 2009-06-29 | 2010-12-06 | 압타바이오 주식회사 | 치료 효능이 있는 변형핵산 및 구아노신을 함유하는 올리고뉴클레오티드 변형체 |
| US9040493B2 (en) * | 2009-07-15 | 2015-05-26 | Santaris Pharma A/S | RNA antagonists targeting GLI2 for the treatment of leukemia |
| JP6155533B2 (ja) * | 2012-02-28 | 2017-07-05 | 国立大学法人東京農工大学 | Ｔｄｐ−４３細胞内存在量関連疾患の認定方法 |
| EP4000597A1 (fr) * | 2020-11-17 | 2022-05-25 | The Boots Company plc | Tétrapeptide et compositions comprenant des tétrapeptides |
| WO2023122762A1 (fr) * | 2021-12-22 | 2023-06-29 | Camp4 Therapeutics Corporation | Modulation de la transcription génique à l'aide d'oligonucléotides antisens ciblant des arn régulateurs |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3172815A (en) * | 1962-04-24 | 1965-03-09 | Warner Lambert Pharmaceutical | Method for preparing reticulo-endo-thelial system stimulant and stimulant thereof |
| US4152423A (en) * | 1971-11-19 | 1979-05-01 | Agence Nationale De Valorisation De La Recherche (Anvar) | Immunological agents |
| FR2160326B1 (fr) * | 1971-11-19 | 1975-02-07 | Anvar | |
| US4010257A (en) * | 1973-02-23 | 1977-03-01 | Burroughs Wellcome Co. | Biological extracts |
| US3976544A (en) * | 1973-06-19 | 1976-08-24 | The Agence Nationale De Valorisation De Le Recherche | Water-soluble immunological adjuvants, in particular for vaccines, obtained from mycobacteria and related microorganisms and process for their extraction |
| FR2374042A1 (fr) * | 1976-06-04 | 1978-07-13 | Merieux Inst | Nouveau medicament immunostimulant et son procede de preparation |
| JPS54140710A (en) * | 1978-03-10 | 1979-11-01 | Mitsui Toatsu Chem Inc | Anti-tumor substance and its preparation |
| DE3011461C2 (de) * | 1980-03-25 | 1986-10-30 | Dr. Madaus & Co, 5000 Köln | Verwendung von Propionibakterien |
| US4520019A (en) * | 1982-04-29 | 1985-05-28 | Ribi Immunochem Research, Inc. | Stable composition and preparation thereof |
| US4579941A (en) * | 1982-08-13 | 1986-04-01 | Mitsuitoatsu Chemicals, Inc. | Thermally-denatured deoxyribonucleic acid MD-011 and antitumor agent |
| US4663306A (en) * | 1983-09-23 | 1987-05-05 | Ribi Immunochem Research, Inc. | Pyridine-soluble extract-refined detoxified endotoxin composition and use |
| GB8404280D0 (en) * | 1984-02-17 | 1984-03-21 | Stanford J L | Biological preparations |
| DE3423234A1 (de) * | 1984-06-23 | 1986-02-06 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Synergistische mischungen von interferonen und tumor-nekrose-faktor |
| US4744984A (en) * | 1985-10-08 | 1988-05-17 | Vetrepharm Research, Inc. | Antiviral immunotherapeutic agent and preparation thereof |
| US4877611A (en) * | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| DE3723075A1 (de) | 1987-07-11 | 1989-01-19 | Boehringer Mannheim Gmbh | Eukaryotische expressionsvektoren mit multimeren enhancer-subelementen, verfahren zu ihrer herstellung und verwendung |
| US4958013A (en) * | 1989-06-06 | 1990-09-18 | Northwestern University | Cholesteryl modified oligonucleotides |
| CA1340994C (fr) * | 1989-09-21 | 2000-05-16 | Rudolf Edgar Dr. Falk | Traitement de maladies et d'etats pathologiques |
| WO1992007095A1 (fr) * | 1990-10-15 | 1992-04-30 | Stratagene | Procede de reaction en chaine de polymerase arbitrairement amorcee destine a produire une empreinte genetique de genomes |
| AU1456092A (en) * | 1991-02-21 | 1992-09-15 | Gilead Sciences, Inc. | Aptamers specific for thrombin and methods of use |
| US6475795B1 (en) * | 1991-07-03 | 2002-11-05 | Meditech Research, Ltd. | Use of hyaluronan in gene therapy |
| US5582981A (en) * | 1991-08-14 | 1996-12-10 | Gilead Sciences, Inc. | Method for identifying an oligonucleotide aptamer specific for a target |
| US5474796A (en) * | 1991-09-04 | 1995-12-12 | Protogene Laboratories, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
| US5523389A (en) * | 1992-09-29 | 1996-06-04 | Isis Pharmaceuticals, Inc. | Inhibitors of human immunodeficiency virus |
| JPH08508976A (ja) * | 1993-01-29 | 1996-09-24 | ベトレフアーム・インコーポレーテツド | 改善化免疫療法用組成物 |
| US5567604A (en) * | 1993-04-23 | 1996-10-22 | Aronex Pharmaceuticals, Inc. | Anti-viral guanosine-rich oligonucleotides |
| CN1154702A (zh) * | 1994-05-25 | 1997-07-16 | 海布里登公司 | 具有抗巨细胞病毒活性的寡核苷酸 |
| WO1996006932A1 (fr) * | 1994-08-30 | 1996-03-07 | Commonwealth Scientific And Industrial Research Organisation | Regulateurs de transcription vegetale issus de circovirus |
| US5643890A (en) | 1995-01-31 | 1997-07-01 | The Board Of Regents Of The University Of Nebraska | Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases |
| IN181358B (fr) * | 1995-02-14 | 1998-05-30 | Bioniche Inc | |
| ZA964446B (en) * | 1995-06-06 | 1996-12-06 | Hoffmann La Roche | Oligonucleotides specific for hepatitis c virus |
| US5990299A (en) * | 1995-08-14 | 1999-11-23 | Icn Pharmaceuticals, Inc. | Control of CD44 gene expression for therapeutic use |
| KR19990071523A (ko) * | 1995-11-21 | 1999-09-27 | 해리 에이. 루스제 | Il－8 및 il－8 수용체에 대한 안티센스올리고누클레오티드에 의한 종양 성장의 억제방법 |
| IT1277025B1 (it) * | 1995-12-04 | 1997-11-04 | Cooperativa Centro Ricerche Po | Classe di oligonucleotidi fosfodiesterici ad attivita' citotossica composizioni farmaceutiche che li contengono e loro uso |
| US6015710A (en) * | 1996-04-09 | 2000-01-18 | The University Of Texas System | Modulation of mammalian telomerase by peptide nucleic acids |
| AU737926B2 (en) * | 1996-05-20 | 2001-09-06 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Oligonucleotides which specifically bind retroviral nucleocapsid proteins |
| DE69809561T2 (de) * | 1997-08-05 | 2003-09-25 | Bioniche Life Science Inc | Zusammensetzung und verfahren zur regulierung von zellproliferation und zelltod |
| US6255473B1 (en) * | 1997-08-29 | 2001-07-03 | Duke University | Presenilin-1 gene promoter |
| MXPA02003108A (es) * | 1999-09-25 | 2003-10-14 | Univ Iowa Res Found | Acidos nucleicos inmunoestimuladores. |
| DK1238070T3 (da) * | 1999-12-13 | 2007-12-03 | Bioniche Life Sciences Inc | Terapeutisk anvendelige syntetiske oligonucleotider |
| US20020091095A1 (en) * | 1999-12-13 | 2002-07-11 | Phillips Nigel C. | Modulation of Fas and FasL expression |
| US7125858B2 (en) * | 1999-12-28 | 2006-10-24 | Bioniche Life Sciences Inc. | Hyaluronic acid in the treatment of cancer |
| MXPA04002530A (es) * | 2001-10-03 | 2004-05-31 | Bioniche Life Sciences Inc | Oligonucleotidos de treitilenglicol colesteril terapeuticamente utiles. |
| EP1497424A1 (fr) * | 2002-04-22 | 2005-01-19 | Bioniche Life Sciences Inc. | Compositions d'oligonucleotides et leur utilisation pour la modulation de reponses immunitaires |
-
2000
- 2000-12-12 DK DK00981117T patent/DK1238070T3/da active
- 2000-12-12 PT PT00981117T patent/PT1238070E/pt unknown
- 2000-12-12 CN CN2008101740188A patent/CN101491536B/zh not_active Expired - Fee Related
- 2000-12-12 ES ES00981117T patent/ES2288883T3/es not_active Expired - Lifetime
- 2000-12-12 EP EP07015976A patent/EP1867718B1/fr not_active Expired - Lifetime
- 2000-12-12 DE DE60036019T patent/DE60036019T2/de not_active Expired - Lifetime
- 2000-12-12 IL IL15019600A patent/IL150196A0/xx unknown
- 2000-12-12 KR KR1020027007557A patent/KR100829646B1/ko not_active IP Right Cessation
- 2000-12-12 AT AT00981117T patent/ATE370231T1/de active
- 2000-12-12 ES ES07015976T patent/ES2340807T3/es not_active Expired - Lifetime
- 2000-12-12 MX MXPA02005842A patent/MXPA02005842A/es active IP Right Grant
- 2000-12-12 US US09/735,363 patent/US7157436B2/en not_active Expired - Fee Related
- 2000-12-12 CZ CZ20022372A patent/CZ20022372A3/cs unknown
- 2000-12-12 AU AU18479/01A patent/AU785212B2/en not_active Ceased
- 2000-12-12 AT AT07015976T patent/ATE455851T1/de not_active IP Right Cessation
- 2000-12-12 DE DE60043759T patent/DE60043759D1/de not_active Expired - Lifetime
- 2000-12-12 EP EP00981117A patent/EP1238070B1/fr not_active Expired - Lifetime
- 2000-12-12 JP JP2001545542A patent/JP4772245B2/ja not_active Expired - Fee Related
- 2000-12-12 CA CA002393808A patent/CA2393808A1/fr not_active Abandoned
- 2000-12-12 CN CNB008188580A patent/CN100445380C/zh not_active Expired - Fee Related
- 2000-12-12 DK DK07015976.9T patent/DK1867718T3/da active
- 2000-12-12 HU HU0300627A patent/HUP0300627A3/hu unknown
- 2000-12-12 WO PCT/CA2000/001467 patent/WO2001044465A2/fr active IP Right Grant
-
2002
- 2002-06-12 IL IL150196A patent/IL150196A/en not_active IP Right Cessation
- 2002-06-13 NO NO20022820A patent/NO330508B1/no not_active IP Right Cessation
-
2006
- 2006-12-18 US US11/641,542 patent/US20070213291A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO330508B1 (no) | Blanding bestaende av syntetisk fosfodiester-nukleotidsekvens og anvendelse derav. | |
| ES2543710T3 (es) | Oligorribonucleótidos inmunoestimulantes que contienen G y U | |
| US7935351B2 (en) | Use of CPG oligodeoxynucleotides to induce angiogenesis | |
| US9090650B2 (en) | Nucleic acid having adjuvanticity and use thereof | |
| Wang et al. | Chemotherapy and chemosensitization of non–small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9 | |
| Gray et al. | CpG-B ODNs potently induce low levels of IFN-αβ and induce IFN-αβ-dependent MHC-I cross-presentation in DCs as effectively as CpG-A and CpG-C ODNs | |
| Rayburn et al. | Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53 | |
| US7662792B2 (en) | Modulation of Fas and FasL expression | |
| Mohri et al. | Increased immunostimulatory activity of polypod-like structured DNA by ligation of the terminal loop structures | |
| KR101017483B1 (ko) | 올리고뉴클레오타이드 조성물 및 세포사멸을 유도하기위한 그의 용도 | |
| AU2007200536A1 (en) | Therapeutically useful synthetic oligonucleotides | |
| Erhardt et al. | Transfection of human monocyte‐derived dendritic cells with CpG oligonucleotides | |
| ES2383671T3 (es) | Modulación de la expresión de Fas y FasL por un oligonucleótido-fosfodiéster sintético y un anticuerpo anti-Fas | |
| CA2420103A1 (fr) | Modulation de l'expression de fas et de fasl | |
| AU2001268863A2 (en) | Modulation of FAS and FASL expression | |
| AU2001268863A1 (en) | Modulation of FAS and FASL expression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |